Applied Biosystems to Invest in VisiGen Biotechnologies
News Jan 05, 2006
VisiGen's technological approach to DNA sequencing is based on the ability to analyse a single molecule of DNA in real time, which has the potential to reduce the cost of sequencing and improve throughput compared to existing commercially available technologies.
Their solution could provide a quantum leap in the scope and scale of research aimed at uncovering the genetic basis of common diseases such as cancer, heart disease and diabetes.
"Applied Biosystems continues to extensively evaluate potential next-generation sequencing technologies," explained Catherine M. Burzik, President of Applied Biosystems.
"We believe that the quality of VisiGen's science and the progress towards the development of single-molecule sequencing technology is quite impressive."
Dr Susan Harding, President and CEO of VisiGen, continued, "VisiGen's approach of monitoring parallel arrays of single molecules could allow large-scale sequencing projects in the areas of cancer and other diseases and could make sequencing-based targeted medicine a reality."
"This investment by Applied Biosystems, and its expertise in DNA sequencing, makes it an ideal partner for us as we work towards commercialisation."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.